[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100639269":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":17,"locations":10,"responsibleParty":27,"collaborators":10,"id":29,"slug":30,"hasResults":31,"nctId":32,"briefTitle":33,"officialTitle":34,"acronym":10,"eligibilityCriteria":35,"healthyVolunteers":31,"sex":36,"minAge":10,"maxAge":10,"enrollmentInfo":37,"targetDuration":10,"studyType":40,"phases":10,"briefSummary":41,"conditions":42,"keywords":45,"overallStatus":47,"whyStopped":10,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":49,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":56,"locationsCount":10},{"fullName":5,"class":6},"Gruppo Italiano Malattie EMatologiche dell'Adulto","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Patients with acute lymphoblastic leukemia treated with CAR-T cells",null,"Pediatric and adult patients with B-cell acute lymhoblastic leukemia treated with approved CAR-T cells in Italy",[13],{"name":14,"affiliation":15,"role":16},"Federico Lussana","Ospedale Papa Giovanni XXIII, Bergamo","PRINCIPAL_INVESTIGATOR",[18,23],{"name":19,"role":20,"phone":21,"phoneExt":10,"email":22},"Paola Fazi","CONTACT","+39 0670390528","p.fazi@gimema.it",{"name":24,"role":20,"phone":25,"phoneExt":10,"email":26},"Enrico Crea","+390670390514","e.crea@gimema.it",{"type":28,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100639269","car-t-treatment-in-pediatric-and-adult-acute-lymphoblastic-leukemia-100639269",false,"NCT07623655","CAR-T Treatment in Pediatric and Adult Acute Lymphoblastic Leukemia","Observational Retrospective and Prospective Multicentric Study on CAR-T Cell for the Treatment of Pediatric and Adult B-cell Acute Lymphoblastic Leukemia","Inclusion Criteria:\n\n1. Diagnosis of ALL R\u002FR CD19+\n2. Patients are pediatric (all patients up to the age of 18) adult (all comers older than 18)\n3. Prescribed treatment with Tisagenlecleucel or Brexucabtagene autoleucel as per approved AIFA criteria, or obecabtagene autoleucel - as well as other products - when available\n4. Provided consent (or did not opposed) for collection and use of patient data per local regulations\n\nExclusion Criteria:\n\nNone\n\n\\-","ALL",{"count":38,"type":39},107,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to evaluate the efficacy of the treatment with approved CAR-T cells in Italy in pediatric and adult patients with acute B-cell lymphoblastic leukemia. The main question it aims to answer is:\n\nwhich is the overall response rate in pediatric and adult patients with acute B-cell lymphoblastic leukemia treated with approved CAR-T cells?\n\nData will be extracted from patients medical records.",[43,44],"Acute Lymphoblastic Leukemia","B-Cell Acute Lymphoblastic Leukaemia",[46],"CAR-T cell, pediatric, adult","NOT_YET_RECRUITING","2026-05-29",{"date":50,"type":51},"2026-06-03","ACTUAL",{"date":53,"type":39},"2026-09-01",{"date":55,"type":39},"2029-12-30",{"name":5,"class":6}]